CN116390735A - 治疗癌症的Bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物 - Google Patents

治疗癌症的Bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物 Download PDF

Info

Publication number
CN116390735A
CN116390735A CN202180066875.XA CN202180066875A CN116390735A CN 116390735 A CN116390735 A CN 116390735A CN 202180066875 A CN202180066875 A CN 202180066875A CN 116390735 A CN116390735 A CN 116390735A
Authority
CN
China
Prior art keywords
compound
combination
use according
day
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202180066875.XA
Other languages
English (en)
Chinese (zh)
Inventor
E·德赛因
L·曼克
M·R·库珀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Les Laboratoires Servier SAS
Original Assignee
Novartis AG
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Les Laboratoires Servier SAS filed Critical Novartis AG
Publication of CN116390735A publication Critical patent/CN116390735A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180066875.XA 2020-07-31 2021-07-30 治疗癌症的Bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物 Withdrawn CN116390735A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063059419P 2020-07-31 2020-07-31
US63/059,419 2020-07-31
EP20195633.1 2020-09-11
EP20195633 2020-09-11
PCT/EP2021/071368 WO2022023514A1 (en) 2020-07-31 2021-07-30 Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
CN116390735A true CN116390735A (zh) 2023-07-04

Family

ID=77595496

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180066875.XA Withdrawn CN116390735A (zh) 2020-07-31 2021-07-30 治疗癌症的Bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物

Country Status (15)

Country Link
US (1) US20230270748A1 (https=)
EP (1) EP4188387A1 (https=)
JP (1) JP2023537290A (https=)
KR (1) KR20230044452A (https=)
CN (1) CN116390735A (https=)
AU (1) AU2021316674A1 (https=)
BR (1) BR112023001307A2 (https=)
CA (1) CA3190276A1 (https=)
CL (1) CL2023000242A1 (https=)
CR (1) CR20230046A (https=)
IL (1) IL300145A (https=)
JO (1) JOP20230013A1 (https=)
MX (1) MX2023001335A (https=)
PH (1) PH12023550205A1 (https=)
WO (1) WO2022023514A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025252168A1 (zh) * 2024-06-06 2025-12-11 苏州亚盛药业有限公司 一种含有Bcl-2/Bcl-xL抑制剂的药物组合及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008975A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2017300738A1 (en) * 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
UY38431A (es) 2018-10-31 2020-05-29 Servier Lab Formulación basada en ciclodextrina de un inhibidor de bcl-2
SI3873894T1 (sl) 2018-10-31 2023-08-31 Les Laboratoires Servier Nova sol Bcl-2 inhibitorja, z njo povezana kristalna oblika, postopek za pripravo le-teh in farmacevtski sestavki, ki jih vsebujejo

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025252168A1 (zh) * 2024-06-06 2025-12-11 苏州亚盛药业有限公司 一种含有Bcl-2/Bcl-xL抑制剂的药物组合及其应用

Also Published As

Publication number Publication date
CA3190276A1 (en) 2022-02-03
KR20230044452A (ko) 2023-04-04
CR20230046A (es) 2023-04-11
WO2022023514A1 (en) 2022-02-03
IL300145A (en) 2023-03-01
MX2023001335A (es) 2023-04-27
BR112023001307A2 (pt) 2023-02-14
US20230270748A1 (en) 2023-08-31
CL2023000242A1 (es) 2023-11-10
PH12023550205A1 (en) 2024-06-24
EP4188387A1 (en) 2023-06-07
JP2023537290A (ja) 2023-08-31
JOP20230013A1 (ar) 2023-01-18
AU2021316674A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
TWI759316B (zh) Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
WO2020257665A1 (en) Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
CN102065865B (zh) 多发性骨髓瘤治疗
US20130041018A1 (en) Method of treating acute myelogenous leukemia
CN116390735A (zh) 治疗癌症的Bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物
CA3030967C (en) Combination of a bcl-2 inhibitor and a mcl-1 uses and pharmaceutical compositions thereof
US20220323465A1 (en) Pharmaceutical combination and use thereof
JP7186731B2 (ja) 血液ガンのためのｍｃｌ－１阻害剤と標準治療処置との組み合わせ、その使用及び医薬組成物
CN113509475A (zh) Bcl-2/bcl-xl抑制剂的组合及相关用途
US20230132982A1 (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
US20220016118A1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
WO2020254299A1 (en) Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
TW202120085A (zh) 抗ccr4抗體抵抗性之癌症的治療劑
CN111728974A (zh) 西奥罗尼用于小细胞肺癌的治疗
JP6708634B2 (ja) 急性骨髄性白血病及び骨髄異形成症候群の併用療法ｉｉｉ
HK40092504A (zh) 治疗癌症的bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物
OA21163A (en) Combination of a BCL-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof.
WO2021079129A1 (en) Dosing regimen
US20240115582A1 (en) Use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] for treating cancers
TW202329968A (zh) 包含mdm2抑制劑、bcl2抑制劑和低甲基化劑的藥物組合及其用於治療血液惡性腫瘤之用途
HK40007956A (en) Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
NZ789582A (en) Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40092504

Country of ref document: HK

WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20230704